Fieldview Capital Management LLC Purchases Shares of 37,976 Globus Medical, Inc. $GMED

Fieldview Capital Management LLC purchased a new stake in Globus Medical, Inc. (NYSE:GMED) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 37,976 shares of the medical device company’s stock, valued at approximately $3,316,000.

Several other hedge funds also recently made changes to their positions in GMED. Bank of Montreal Can increased its holdings in shares of Globus Medical by 15,317.1% during the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after purchasing an additional 3,351,380 shares during the period. Alliancebernstein L.P. grew its stake in shares of Globus Medical by 1,303.9% during the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock worth $117,700,000 after buying an additional 1,908,795 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new stake in shares of Globus Medical during the fourth quarter worth $90,411,000. Norges Bank acquired a new position in shares of Globus Medical during the fourth quarter worth $89,922,000. Finally, ANTIPODES PARTNERS Ltd lifted its holdings in shares of Globus Medical by 49,020.3% during the third quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company’s stock worth $51,034,000 after purchasing an additional 889,229 shares during the period. 95.16% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on GMED. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Wells Fargo & Company reduced their target price on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Truist Financial set a $115.00 price objective on shares of Globus Medical in a research report on Wednesday, February 25th. Finally, Wall Street Zen cut shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Globus Medical currently has a consensus rating of “Moderate Buy” and an average target price of $106.36.

Insider Activity at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 18.38% of the company’s stock.

Globus Medical Price Performance

Shares of NYSE:GMED opened at $80.44 on Friday. The company’s fifty day moving average price is $85.77 and its 200-day moving average price is $88.10. The firm has a market capitalization of $10.92 billion, a price-to-earnings ratio of 18.71, a PEG ratio of 1.66 and a beta of 0.95. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, equities research analysts expect that Globus Medical, Inc. will post 4.74 EPS for the current year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.